- Cadila Healthcare Ltd has become India’s second-most valuable pharmaceutical company in terms of market capitalisation, ahead of drug makers such as Lupin Ltd, Dr Reddy’s Laboratories Ltd and Cipla Ltd that have higher revenues. Now it ranks at the 47th position in overall market cap among all industries ranking on the BSE. Sun Pharmaceuticals Industries Ltd continues to be the most valued pharma company in India .
- Pharma companies face increase in regulatory issues from US health regulator.The tight regulatory vigil by the US Food and Drug Administration (USFDA) has become a major concern for the pharmaceutical industry.
- NPPA’s fixed the ceiling prices of 31 more drug formulations taking the total number of drug formulations to 761 since April 2016.
- The government’s decision to make it mandatory for doctors to prescribe medicines using their generic names would “kill the pharmaceutical industry”, the Indian Drug Manufacturers’ Association (IDMA) wrote in a letter to Prime Minister Narendra Modi.
- A new study published in the journal “Infection’ alleges. The pharma industry in Hyderabad is polluting the environment with antimicrobials which IS contributing to a rise in drug-resistant infections. Indian authorities have not done enough to ensure efficient treatment of waste water discharged by the pharma industry. Hyderabad is a global market for bulk drug purchasing with 50% of India’s drug exportS.
- Pricing pressure in the biggest market, the US, and sticky compliance issues have significantly eroded value of pharmaceutical companies over last two years. India’s largest drug maker, Sun Pharmaceutical Industries Ltd, has been the worst performer with its market cap down 48%. Other pharma majors such as Lupin Ltd, Dr. Reddy’s Laboratories Ltd, and Cipla Ltd have seen their market cap fall by 39%, 31% and 22%, respectively.
- Glenmark Pharmaceuticals has received ANDA approval by the United States Food & Drug Administration (U.S. FDA) for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg,
Language »